Report cover image

Idiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published Aug 31, 2023
Length 70 Pages
SKU # GBDT18201387

Description

Idiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in IH therapeutics.
  • More than 280,000 diagnosed prevalent cases of IH are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for IH.
  • The most recent guideline for the diagnosis and treatment of IH was published by the American Academy of Sleep Medicine.
  • The IH pipeline consists of 56 drugs spanning all stages of development (discovery to late-stage clinical development), with only 3.5% of drugs in Phase III.
  • Over the past 10 years, significant development for IH has taken place, with around 89 trials conducted overall.
  • Licensing agreements were the most prominent type of deal ventured in the IH space globally.
Scope

GlobalData’s IH: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the IH market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IH market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

70 Pages
  • Key Findings
    • Disease Etiology Disease Overview
    • Epidemiology Overview – Diagnosed Prevalent Cases of IH in 2023 and 2028
    • Treatment Guidelines
    • Marketed Drugs – Leading Marketed Drugs in IH
    • Marketed Drugs – Overview by Mechanism of Action
    • Marketed Drugs – Overview by Route of Administration
    • Marketed Drugs Profile: Jazz Pharmaceuticals's Xywav
    • Marketed Drugs Profile: Bioprojet's Ozawade
    • Marketed Drugs – Annual Cost of Therapy
    • Marketed Drugs – Time to Pricing and Reimbursement for Ozawade
    • Marketed Drugs – Time to Pricing and Reimbursement for Xywav and Modiodal
    • Pipeline Drugs Overview – Mid-to-Late-Stage Pipeline Drugs in IH
    • Pipeline Drugs – Overview by Development Stage
    • Pipeline Drugs – Overview by Mechanism of Action
    • Pipeline Drugs – Overview by Route of Administration
    • Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in IH
    • Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in CNS and IH
    • Clinical Trials in IH – Historical Overview
    • Clinical Trials in IH – Overview by Phase
    • Clinical Trials in IH – Overview by Status
    • Clinical Trials in IH – Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in IH – Trials with a Virtual Component
    • Clinical Trials in IH – Geographic Overview
    • Clinical Trials in IH – Single-Country and Multinational Trials by Region
    • Clinical Trials in IH – Top Sponsors with Breakdown by Phase
    • Clinical Trials in IH – Top Sponsors with Breakdown by Status
    • Clinical Trials in IH – Overview by Endpoint Status
    • Clinical Trials in IH – Overview by Race and Ethnicity
    • Clinical Trials in IH – Enrollment Data
    • Clinical Trials in IH – Overview of Sites by Geography
    • Clinical Trials in IH – Top 20 Countries for Trial Sites
    • Clinical Trials in IH – Top 20 Sites Globally
    • Clinical Trials – Feasibility Analysis: Geography Overview
    • Clinical Trials – Feasibility Analysis: Benchmark Models for IH
    • Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in IH by Region
    • Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in IH
    • Commercial Assessment – Key Market Players in IH
    • Future Market Catalysts – Upcoming Market Catalysts in IH
    • Methodology
    • Methodology – Sales Forecasts
    • Methodology – Pricing and Reimbursement
    • Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
    • Contact Us – A Global Network of Offices
    • About GlobalData

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us